

ASX Release

## Non-Renounceable Rights Issue: Shortfall Notice

## Sydney, Tuesday 19th December 2017

Memphasys Limited (ASX: MEM) ("Memphasys" or the "Company") advises that the Non-Renounceable Rights Issue Offer announced to the ASX on 28th November 2017 ("Rights Issue"), closed on 15th December 2017. The Rights Issue offered eligible shareholders registered on the Record Date the ability to subscribe for Non-Renounceable Rights ("New Shares") based on one (1) fully paid ordinary share for every one (1) share held at an issue price of \$0.001 per share to raise \$699,821. Total applications for New Shares raising gross proceeds of \$431,624 were received, excluding applications for additional Shortfall Shares.

The New Shares will be allotted on 22 December 2017, as per the timetable for the Rights Issue. The Offer is fully underwritten and managed by Patersons Securities Limited (ACN 008 896 311), holder of an Australian Financial Services Licence (AFSL No. 239 052) who will place the Shortfall Shares on or about 27 December 2017.

The results of the Rights Issue are as follows:

Number of New (Entitlement) Shares: 431,624,052

Shortfall Shares: 268,197,308

Total Number of Shares: 699,821,360

## For further information please contact:

Alison Coutts
Executive Chairman
+61 2 8415 7300
alison.coutts@memphasys.com

## **About Memphasys:**

Memphasys Limited **(ASX: MEM)** specialises in biological separations for high value commercial applications. The Company's patented membrane processes in combination with electrophoresis, the application of an electrical potential difference across a fluid, enable the separation of high value substances or contaminants from the fluid in which they are contained.

The main application of the technology is the separation of the most viable sperm cells for artificial reproduction, most particularly for human IVF.